About US
Contact us
-
Just wait, Perrigo investor urges. We can get the same return--without a Mylan dealAll eyes are on Perrigo's investors, who will have to decide whether to accept Mylan's offer when the wannabe acquirer takes it to them next Monday. And Israeli businessman Mori Arking, for one, plans2015/9/11
-
Horizon steps up its official Depomed pursuit with campaign websiteHorizon Pharma($HZNP)has officially begun mailing solicitation materials to shareholders of unwilling M&A target Depomed($DEPO), including a letter related to its efforts to call the two special m2015/9/11
-
Cost watchdog says PCSK9 meds should cost 85% less. Realistic or not?Payers ready to balk at the cost of new cholesterol-fighting PCSK9 drugs could have some new backing. A not-for-profit drug pricing watchdog, which analyzed data on the drugs, says they should cost on2015/9/10
-
Icahn casts his eye on Vivus with tender offer for convertible notesActivist investor Carl Icahn is jumping into the biopharma fray once again, this time getting involved with struggling obesity drugmaker Vivus. On Wednesday, his Icahn Enterprises offered to buy up a2015/9/10
-
Already riding naloxone boom, Amphastar plots nasal spray to rival old formulasA surge ofopioid-related deaths in the U.S. has created an opportunity for pharma companies that make the overdose antidotenaloxone. The drug's price has risen tenfold in recent years,Bloombergreports2015/9/9
-
Novartis CEO: Payers not sold on performance pricing yet, but that'll changeNovartis ($NVS) CEO Joe Jimenez sees a couple of rays of hope for drug spending--and for the viability of higher-priced meds. Big Data, for one. And performance-based pricing for another. In an inter2015/9/9
-
UPDATED: AstraZeneca scores FDA nod for long-term Brilinta useAstraZeneca's ($AZN) blood thinnerBrilintais officially one step closer to living up to the $3.5 billion ambitions the British pharma laid out last February. TheFDAhas handed down an approval for long2015/9/7
-
India's Cipla gets U.S. beachhead with $550M deal for 2 generics operationsIndia'sCiplamade its name in the west as a leader in challenging Big Pharma patents on expensive drugs in an effort to cut their prices in a country with a large need and little money. But it has lagg2015/9/7
-
UPDATED: AstraZeneca scores FDA nod for long-term Brilinta useAstraZeneca's ($AZN) blood thinnerBrilintais officially one step closer to living up to the $3.5 billion ambitions the British pharma laid out last February. TheFDAhas handed down an approval for long2015/9/6
-
India's Cipla gets U.S. beachhead with $550M deal for 2 generics operationsIndia'sCiplamade its name in the west as a leader in challenging Big Pharma patents on expensive drugs in an effort to cut their prices in a country with a large need and little money. But it has lagg2015/9/6